We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker (BRKR) Down 7.4% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Bruker (BRKR - Free Report) . Shares have lost about 7.4% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Bruker due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Bruker Q2 Earnings Beat Estimates
Bruker Corporation delivered adjusted earnings per share (EPS) of 33 cents in the second quarter of 2019, up 32% from the year-ago figure. The figure surpassed the Zacks Consensus Estimate by 6.5%.
On a reported basis, earnings were 23 cents a share compared with the year-earlier figure of 20 cents.
Revenues in Detail
Bruker registered revenues of $490.2 million in the second quarter, up 10.5% year over year. The top line also surpassed the Zacks Consensus Estimate by 2.7%.
Excluding a positive effect of 8.7% from acquisitions and a 3% negative impact from changes in foreign currency rates, Bruker recorded organic revenue growth of 4.8% year over year.
The company’s organic revenue growth was driven by strength in Bruker Scientific Instruments (BSI) and BEST segments.
Geographically, the United States saw 16.4% growth in the reported quarter. Meanwhile, European revenues rose 3.4% year over year. Also, Asia Pacific revenues grew 13.5%. In Other category, revenues rose 12.6%.
During the second quarter, Bruker’s BioSpin Group revenues increased 7.9% from the year-ago quarter. Revenues in the NANO group rose 12.3%, fueled by a strong uptrend in the academic research and industrial research markets. CALID revenues were up 9.8% year over year.
Margin Trend
Gross margin in the quarter under review expanded 75 basis points (bps) to 47%. Meanwhile, selling, general & administrative expenses climbed 12.6% to $124.5 million. Research and development expenses went up 11.2% year over year to $48.5 million. Overall, adjusted operating margin expanded 22 bps to 11.7%.
Financial Position
Bruker exited the second quarter of 2019 with cash and cash equivalents of $282.5 million, down from $298.8 million at the end of the first quarter. Year-to-date net cash provided by operating activities was $24.8 million in comparison to $79.9 million a year ago.
2019 Guidance
Bruker reaffirmed its 2019 outlook. For the full year, the company reiterates revenue growth projection at 7-8%, including nearly 4.5-5.5% organic revenue rise and an estimated 2.5% headwind from adverse foreign currency translation. The Zacks Consensus Estimate for the metric is $2.04 billion.
The company continues to envision year-over-year expansion of 90-120 bps in adjusted operating margin over its fiscal 2018 non-GAAP operating margin of 16.8%.
For 2019, Bruker maintains adjusted EPS view at the range of $1.57-$1.61. The Zacks Consensus Estimate of $1.62 is above the guided range.
How Have Estimates Been Moving Since Then?
Fresh estimates followed a downward path over the past two months. The consensus estimate has shifted -7.57% due to these changes.
VGM Scores
Currently, Bruker has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Bruker has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bruker (BRKR) Down 7.4% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Bruker (BRKR - Free Report) . Shares have lost about 7.4% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Bruker due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Bruker Q2 Earnings Beat Estimates
Bruker Corporation delivered adjusted earnings per share (EPS) of 33 cents in the second quarter of 2019, up 32% from the year-ago figure. The figure surpassed the Zacks Consensus Estimate by 6.5%.
On a reported basis, earnings were 23 cents a share compared with the year-earlier figure of 20 cents.
Revenues in Detail
Bruker registered revenues of $490.2 million in the second quarter, up 10.5% year over year. The top line also surpassed the Zacks Consensus Estimate by 2.7%.
Excluding a positive effect of 8.7% from acquisitions and a 3% negative impact from changes in foreign currency rates, Bruker recorded organic revenue growth of 4.8% year over year.
The company’s organic revenue growth was driven by strength in Bruker Scientific Instruments (BSI) and BEST segments.
Geographically, the United States saw 16.4% growth in the reported quarter. Meanwhile, European revenues rose 3.4% year over year. Also, Asia Pacific revenues grew 13.5%. In Other category, revenues rose 12.6%.
During the second quarter, Bruker’s BioSpin Group revenues increased 7.9% from the year-ago quarter. Revenues in the NANO group rose 12.3%, fueled by a strong uptrend in the academic research and industrial research markets. CALID revenues were up 9.8% year over year.
Margin Trend
Gross margin in the quarter under review expanded 75 basis points (bps) to 47%. Meanwhile, selling, general & administrative expenses climbed 12.6% to $124.5 million. Research and development expenses went up 11.2% year over year to $48.5 million. Overall, adjusted operating margin expanded 22 bps to 11.7%.
Financial Position
Bruker exited the second quarter of 2019 with cash and cash equivalents of $282.5 million, down from $298.8 million at the end of the first quarter. Year-to-date net cash provided by operating activities was $24.8 million in comparison to $79.9 million a year ago.
2019 Guidance
Bruker reaffirmed its 2019 outlook. For the full year, the company reiterates revenue growth projection at 7-8%, including nearly 4.5-5.5% organic revenue rise and an estimated 2.5% headwind from adverse foreign currency translation. The Zacks Consensus Estimate for the metric is $2.04 billion.
The company continues to envision year-over-year expansion of 90-120 bps in adjusted operating margin over its fiscal 2018 non-GAAP operating margin of 16.8%.
For 2019, Bruker maintains adjusted EPS view at the range of $1.57-$1.61. The Zacks Consensus Estimate of $1.62 is above the guided range.
How Have Estimates Been Moving Since Then?
Fresh estimates followed a downward path over the past two months. The consensus estimate has shifted -7.57% due to these changes.
VGM Scores
Currently, Bruker has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Bruker has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.